Abstract
Anti-complement strategies appear to hold great promise for the development of stroke therapeutics. Yet caution should be exercised. It is clear that the complement cascade is a complex and intricate system with widely varied effects, and if any knowledge has been gained from the many failed attempts at translating stroke therapies to the bedside, it is that cavalier application of under-elucidated therapies that leads to wasted resources and the potential for poor patient outcomes.
